FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:NF1-RBX1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: NF1-RBX1
FusionPDB ID: 58700
FusionGDB2.0 ID: 58700
HgeneTgene
Gene symbol

NF1

RBX1

Gene ID

4763

9978

Gene nameneurofibromin 1ring-box 1
SynonymsNFNS|VRNF|WSSBA554C12.1|RNF75|ROC1
Cytomap

17q11.2

22q13.2

Type of geneprotein-codingprotein-coding
Descriptionneurofibrominneurofibromatosis 1neurofibromatosis-related protein NF-1truncated neurofibromin 1E3 ubiquitin-protein ligase RBX1E3 ubiquitin-protein transferase RBX1RING finger protein 75RING-box protein 1ZYP proteinregulator of cullins 1ring-box 1, E3 ubiquitin protein ligase
Modification date2020032220200327
UniProtAcc

P21359

Main function of 5'-partner protein: FUNCTION: Stimulates the GTPase activity of Ras. NF1 shows greater affinity for Ras GAP, but lower specific activity. May be a regulator of Ras activity. {ECO:0000269|PubMed:2121371, ECO:0000269|PubMed:8417346}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000356175, ENST00000358273, 
ENST00000431387, ENST00000417592, 
ENST00000444181, ENST00000581113, 
ENST00000216225, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score47 X 26 X 21=2566211 X 8 X 10=880
# samples 6914
** MAII scorelog2(69/25662*10)=-5.21689344093196
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(14/880*10)=-2.65207669657969
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: NF1 [Title/Abstract] AND RBX1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: NF1 [Title/Abstract] AND RBX1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)NF1(29422387)-RBX1(41349559), # samples:2
Anticipated loss of major functional domain due to fusion event.NF1-RBX1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
NF1-RBX1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
NF1-RBX1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
NF1-RBX1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
NF1-RBX1 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF.
NF1-RBX1 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF.
NF1-RBX1 seems lost the major protein functional domain in Tgene partner, which is a epigenetic factor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneNF1

GO:0043547

positive regulation of GTPase activity

2121371

TgeneRBX1

GO:0006513

protein monoubiquitination

22358839

TgeneRBX1

GO:0016567

protein ubiquitination

15103331|17543862|20389280

TgeneRBX1

GO:0031146

SCF-dependent proteasomal ubiquitin-dependent protein catabolic process

15103331

TgeneRBX1

GO:0043161

proteasome-mediated ubiquitin-dependent protein catabolic process

20389280

TgeneRBX1

GO:0045116

protein neddylation

19250909



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:29422387/chr22:41349559)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across NF1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across RBX1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000356175NF1chr1729422387+ENST00000216225RBX1chr2241349559+1513443254691145
ENST00000358273NF1chr1729422387+ENST00000216225RBX1chr2241349559+1513443254691145
ENST00000431387NF1chr1729422387+ENST00000216225RBX1chr2241349559+1463393204641145
ENST00000356175NF1chr1729422387+ENST00000216225RBX1chr2241349558+1513443254691145
ENST00000358273NF1chr1729422387+ENST00000216225RBX1chr2241349558+1513443254691145
ENST00000431387NF1chr1729422387+ENST00000216225RBX1chr2241349558+1463393204641145

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000356175ENST00000216225NF1chr1729422387+RBX1chr2241349559+0.308978170.69102186
ENST00000358273ENST00000216225NF1chr1729422387+RBX1chr2241349559+0.308978170.69102186
ENST00000431387ENST00000216225NF1chr1729422387+RBX1chr2241349559+0.38818530.61181474
ENST00000356175ENST00000216225NF1chr1729422387+RBX1chr2241349558+0.308978170.69102186
ENST00000358273ENST00000216225NF1chr1729422387+RBX1chr2241349558+0.308978170.69102186
ENST00000431387ENST00000216225NF1chr1729422387+RBX1chr2241349558+0.38818530.61181474

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for NF1-RBX1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
NF1chr1729422387RBX1chr224134955839362VEWVQAVVSRFDEQWNAVALWAWDIV
NF1chr1729422387RBX1chr224134955844362VEWVQAVVSRFDEQWNAVALWAWDIV
NF1chr1729422387RBX1chr224134955939362VEWVQAVVSRFDEQWNAVALWAWDIV
NF1chr1729422387RBX1chr224134955944362VEWVQAVVSRFDEQWNAVALWAWDIV

Top

Potential FusionNeoAntigen Information of NF1-RBX1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
NF1-RBX1_29422387_41349558.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
NF1-RBX1chr1729422387chr2241349558443HLA-B57:01VSRFDEQW0.99980.9945715
NF1-RBX1chr1729422387chr2241349558443HLA-B58:02VSRFDEQW0.99890.9848715
NF1-RBX1chr1729422387chr2241349558443HLA-B58:01VSRFDEQW0.99830.9887715
NF1-RBX1chr1729422387chr2241349558443HLA-B39:01EQWNAVAL0.99520.97771220
NF1-RBX1chr1729422387chr2241349558443HLA-B15:10EQWNAVAL0.98150.76571220
NF1-RBX1chr1729422387chr2241349558443HLA-B15:37EQWNAVAL0.97880.8011220
NF1-RBX1chr1729422387chr2241349558443HLA-B27:07SRFDEQWNA0.99950.7407817
NF1-RBX1chr1729422387chr2241349558443HLA-B27:04SRFDEQWNA0.99930.7946817
NF1-RBX1chr1729422387chr2241349558443HLA-B27:05SRFDEQWNA0.99920.9409817
NF1-RBX1chr1729422387chr2241349558443HLA-B57:01VVSRFDEQW0.99790.9941615
NF1-RBX1chr1729422387chr2241349558443HLA-B39:06SRFDEQWNA0.9970.9343817
NF1-RBX1chr1729422387chr2241349558443HLA-B58:01VVSRFDEQW0.99510.9878615
NF1-RBX1chr1729422387chr2241349558443HLA-B39:24SRFDEQWNA0.99490.7173817
NF1-RBX1chr1729422387chr2241349558443HLA-B58:02VVSRFDEQW0.99270.9868615
NF1-RBX1chr1729422387chr2241349558443HLA-B39:01SRFDEQWNA0.98870.9614817
NF1-RBX1chr1729422387chr2241349558443HLA-B15:17VVSRFDEQW0.98580.9597615
NF1-RBX1chr1729422387chr2241349558443HLA-B18:01DEQWNAVAL0.9790.93841120
NF1-RBX1chr1729422387chr2241349558443HLA-B44:03EQWNAVALW0.97130.99111221
NF1-RBX1chr1729422387chr2241349558443HLA-B57:03VVSRFDEQW0.94580.9961615
NF1-RBX1chr1729422387chr2241349558443HLA-B15:37DEQWNAVAL0.88510.83221120
NF1-RBX1chr1729422387chr2241349558443HLA-B15:16VVSRFDEQW0.87510.941615
NF1-RBX1chr1729422387chr2241349558443HLA-B44:02EQWNAVALW0.86860.73651221
NF1-RBX1chr1729422387chr2241349558443HLA-A32:13VVSRFDEQW0.82750.9592615
NF1-RBX1chr1729422387chr2241349558443HLA-B53:01EQWNAVALW0.82640.87011221
NF1-RBX1chr1729422387chr2241349558443HLA-B53:01VVSRFDEQW0.7290.6159615
NF1-RBX1chr1729422387chr2241349558443HLA-A32:13EQWNAVALW0.70690.9921221
NF1-RBX1chr1729422387chr2241349558443HLA-B13:01EQWNAVALW0.20280.99651221
NF1-RBX1chr1729422387chr2241349558443HLA-B27:02SRFDEQWNAV0.99990.8623818
NF1-RBX1chr1729422387chr2241349558443HLA-B27:05SRFDEQWNAV0.99990.9495818
NF1-RBX1chr1729422387chr2241349558443HLA-B27:04SRFDEQWNAV0.99990.8048818
NF1-RBX1chr1729422387chr2241349558443HLA-B27:07SRFDEQWNAV0.99980.8755818
NF1-RBX1chr1729422387chr2241349558443HLA-B57:01AVVSRFDEQW0.99950.9954515
NF1-RBX1chr1729422387chr2241349558443HLA-B39:06SRFDEQWNAV0.99870.9617818
NF1-RBX1chr1729422387chr2241349558443HLA-B39:24SRFDEQWNAV0.99820.8229818
NF1-RBX1chr1729422387chr2241349558443HLA-B44:03DEQWNAVALW0.9980.9871121
NF1-RBX1chr1729422387chr2241349558443HLA-B58:01AVVSRFDEQW0.9970.991515
NF1-RBX1chr1729422387chr2241349558443HLA-B44:02DEQWNAVALW0.99460.53851121
NF1-RBX1chr1729422387chr2241349558443HLA-B44:05DEQWNAVALW0.97240.59521121
NF1-RBX1chr1729422387chr2241349558443HLA-B57:03AVVSRFDEQW0.97180.9952515
NF1-RBX1chr1729422387chr2241349558443HLA-A32:13AVVSRFDEQW0.79820.9677515
NF1-RBX1chr1729422387chr2241349558443HLA-B57:01QAVVSRFDEQW0.99990.9929415
NF1-RBX1chr1729422387chr2241349558443HLA-B39:06SRFDEQWNAVA0.99970.9829819
NF1-RBX1chr1729422387chr2241349558443HLA-B58:02QAVVSRFDEQW0.99960.9879415
NF1-RBX1chr1729422387chr2241349558443HLA-B58:01QAVVSRFDEQW0.99910.9847415
NF1-RBX1chr1729422387chr2241349558443HLA-B57:03QAVVSRFDEQW0.99790.9937415
NF1-RBX1chr1729422387chr2241349558443HLA-B40:01RFDEQWNAVAL0.90610.6695920
NF1-RBX1chr1729422387chr2241349558443HLA-B39:05EQWNAVAL0.99330.97021220
NF1-RBX1chr1729422387chr2241349558443HLA-B27:14SRFDEQWNA0.99930.8539817
NF1-RBX1chr1729422387chr2241349558443HLA-C04:10RFDEQWNAV0.99930.9874918
NF1-RBX1chr1729422387chr2241349558443HLA-C04:07RFDEQWNAV0.99920.9874918
NF1-RBX1chr1729422387chr2241349558443HLA-B73:01SRFDEQWNA0.99780.9487817
NF1-RBX1chr1729422387chr2241349558443HLA-B39:09SRFDEQWNA0.98870.8628817
NF1-RBX1chr1729422387chr2241349558443HLA-B39:12SRFDEQWNA0.98830.9651817
NF1-RBX1chr1729422387chr2241349558443HLA-C07:95SRFDEQWNA0.97690.8874817
NF1-RBX1chr1729422387chr2241349558443HLA-B27:03SRFDEQWNA0.96550.9448817
NF1-RBX1chr1729422387chr2241349558443HLA-B44:10DEQWNAVAL0.95890.60431120
NF1-RBX1chr1729422387chr2241349558443HLA-B44:08EQWNAVALW0.90250.87691221
NF1-RBX1chr1729422387chr2241349558443HLA-B44:06EQWNAVALW0.84510.55071221
NF1-RBX1chr1729422387chr2241349558443HLA-B44:04EQWNAVALW0.84020.66761221
NF1-RBX1chr1729422387chr2241349558443HLA-C04:14RFDEQWNAV0.74230.9862918
NF1-RBX1chr1729422387chr2241349558443HLA-B14:03DEQWNAVAL0.63290.94391120
NF1-RBX1chr1729422387chr2241349558443HLA-B39:09DEQWNAVAL0.58720.91771120
NF1-RBX1chr1729422387chr2241349558443HLA-B39:05DEQWNAVAL0.5690.95921120
NF1-RBX1chr1729422387chr2241349558443HLA-B27:14SRFDEQWNAV0.99990.8755818
NF1-RBX1chr1729422387chr2241349558443HLA-B73:01SRFDEQWNAV0.99870.978818
NF1-RBX1chr1729422387chr2241349558443HLA-B39:12SRFDEQWNAV0.99680.9818818
NF1-RBX1chr1729422387chr2241349558443HLA-B27:03SRFDEQWNAV0.9960.9527818
NF1-RBX1chr1729422387chr2241349558443HLA-B44:04DEQWNAVALW0.99430.5441121
NF1-RBX1chr1729422387chr2241349558443HLA-B44:08DEQWNAVALW0.9920.65611121
NF1-RBX1chr1729422387chr2241349558443HLA-B27:14VSRFDEQWNA0.94080.8139717
NF1-RBX1chr1729422387chr2241349558443HLA-B73:01VSRFDEQWNA0.81110.9565717
NF1-RBX1chr1729422387chr2241349558443HLA-C04:07RFDEQWNAVAL10.9651920
NF1-RBX1chr1729422387chr2241349558443HLA-B27:14SRFDEQWNAVA10.8939819
NF1-RBX1chr1729422387chr2241349558443HLA-C04:10RFDEQWNAVAL10.9688920
NF1-RBX1chr1729422387chr2241349558443HLA-B73:01SRFDEQWNAVA0.99980.9835819
NF1-RBX1chr1729422387chr2241349558443HLA-C04:14RFDEQWNAVAL0.99590.9777920
NF1-RBX1chr1729422387chr2241349558443HLA-B73:01VVSRFDEQWNA0.9570.9628617
NF1-RBX1chr1729422387chr2241349558443HLA-B57:10VSRFDEQW0.99980.9945715
NF1-RBX1chr1729422387chr2241349558443HLA-B57:04VSRFDEQW0.99920.8569715
NF1-RBX1chr1729422387chr2241349558443HLA-B58:06VSRFDEQW0.99840.9634715
NF1-RBX1chr1729422387chr2241349558443HLA-B15:09EQWNAVAL0.94530.7941220
NF1-RBX1chr1729422387chr2241349558443HLA-B18:04EQWNAVAL0.84570.93391220
NF1-RBX1chr1729422387chr2241349558443HLA-C04:03RFDEQWNAV0.99950.9897918
NF1-RBX1chr1729422387chr2241349558443HLA-B27:09SRFDEQWNA0.99950.9321817
NF1-RBX1chr1729422387chr2241349558443HLA-B27:10SRFDEQWNA0.99930.8879817
NF1-RBX1chr1729422387chr2241349558443HLA-C04:01RFDEQWNAV0.99920.9874918
NF1-RBX1chr1729422387chr2241349558443HLA-B27:06SRFDEQWNA0.99920.8033817
NF1-RBX1chr1729422387chr2241349558443HLA-B27:08SRFDEQWNA0.99920.8501817
NF1-RBX1chr1729422387chr2241349558443HLA-C18:01RFDEQWNAV0.99870.9868918
NF1-RBX1chr1729422387chr2241349558443HLA-B57:10VVSRFDEQW0.99790.9941615
NF1-RBX1chr1729422387chr2241349558443HLA-B57:04VVSRFDEQW0.99440.8972615
NF1-RBX1chr1729422387chr2241349558443HLA-B39:31SRFDEQWNA0.9910.9617817
NF1-RBX1chr1729422387chr2241349558443HLA-B58:06VVSRFDEQW0.98930.9676615
NF1-RBX1chr1729422387chr2241349558443HLA-B18:04DEQWNAVAL0.98710.94531120
NF1-RBX1chr1729422387chr2241349558443HLA-B18:07DEQWNAVAL0.98390.90811120
NF1-RBX1chr1729422387chr2241349558443HLA-B18:05DEQWNAVAL0.9790.93841120
NF1-RBX1chr1729422387chr2241349558443HLA-C07:01SRFDEQWNA0.97550.8859817
NF1-RBX1chr1729422387chr2241349558443HLA-B40:04DEQWNAVAL0.97550.77661120
NF1-RBX1chr1729422387chr2241349558443HLA-B18:08DEQWNAVAL0.97470.94471120
NF1-RBX1chr1729422387chr2241349558443HLA-B18:06DEQWNAVAL0.97390.94291120
NF1-RBX1chr1729422387chr2241349558443HLA-C06:08SRFDEQWNA0.97360.9938817
NF1-RBX1chr1729422387chr2241349558443HLA-B44:13EQWNAVALW0.97130.99111221
NF1-RBX1chr1729422387chr2241349558443HLA-B44:26EQWNAVALW0.97130.99111221
NF1-RBX1chr1729422387chr2241349558443HLA-B44:07EQWNAVALW0.97130.99111221
NF1-RBX1chr1729422387chr2241349558443HLA-B18:03DEQWNAVAL0.97120.93331120
NF1-RBX1chr1729422387chr2241349558443HLA-B57:02VVSRFDEQW0.95530.9804615
NF1-RBX1chr1729422387chr2241349558443HLA-A32:01VVSRFDEQW0.8980.9488615
NF1-RBX1chr1729422387chr2241349558443HLA-B44:22EQWNAVALW0.86860.73651221
NF1-RBX1chr1729422387chr2241349558443HLA-B15:13VVSRFDEQW0.86430.82615
NF1-RBX1chr1729422387chr2241349558443HLA-C04:04RFDEQWNAV0.84470.9933918
NF1-RBX1chr1729422387chr2241349558443HLA-B15:13EQWNAVALW0.82920.96561221
NF1-RBX1chr1729422387chr2241349558443HLA-B15:24EQWNAVALW0.80540.98251221
NF1-RBX1chr1729422387chr2241349558443HLA-B18:11DEQWNAVAL0.74750.89881120
NF1-RBX1chr1729422387chr2241349558443HLA-B53:02EQWNAVALW0.73620.89951221
NF1-RBX1chr1729422387chr2241349558443HLA-B44:21EQWNAVALW0.71710.55631221
NF1-RBX1chr1729422387chr2241349558443HLA-B39:11DEQWNAVAL0.62710.85861120
NF1-RBX1chr1729422387chr2241349558443HLA-B53:02VVSRFDEQW0.62250.5635615
NF1-RBX1chr1729422387chr2241349558443HLA-B39:31DEQWNAVAL0.5870.97031120
NF1-RBX1chr1729422387chr2241349558443HLA-C07:22SRFDEQWNA0.55240.7994817
NF1-RBX1chr1729422387chr2241349558443HLA-B41:03DEQWNAVAL0.5320.71121120
NF1-RBX1chr1729422387chr2241349558443HLA-C07:04RFDEQWNAV0.52170.9721918
NF1-RBX1chr1729422387chr2241349558443HLA-A25:01EQWNAVALW0.44930.93281221
NF1-RBX1chr1729422387chr2241349558443HLA-B15:24VVSRFDEQW0.40550.9721615
NF1-RBX1chr1729422387chr2241349558443HLA-C06:02SRFDEQWNA0.03020.9946817
NF1-RBX1chr1729422387chr2241349558443HLA-C06:17SRFDEQWNA0.03020.9946817
NF1-RBX1chr1729422387chr2241349558443HLA-B27:06SRFDEQWNAV0.99990.8084818
NF1-RBX1chr1729422387chr2241349558443HLA-B27:09SRFDEQWNAV0.99990.9446818
NF1-RBX1chr1729422387chr2241349558443HLA-B27:08SRFDEQWNAV0.99990.8901818
NF1-RBX1chr1729422387chr2241349558443HLA-B27:10SRFDEQWNAV0.99990.8842818
NF1-RBX1chr1729422387chr2241349558443HLA-B57:10AVVSRFDEQW0.99950.9954515
NF1-RBX1chr1729422387chr2241349558443HLA-B57:04AVVSRFDEQW0.99860.9078515
NF1-RBX1chr1729422387chr2241349558443HLA-B39:31SRFDEQWNAV0.9980.9796818
NF1-RBX1chr1729422387chr2241349558443HLA-B44:26DEQWNAVALW0.9980.9871121
NF1-RBX1chr1729422387chr2241349558443HLA-B44:07DEQWNAVALW0.9980.9871121
NF1-RBX1chr1729422387chr2241349558443HLA-B44:13DEQWNAVALW0.9980.9871121
NF1-RBX1chr1729422387chr2241349558443HLA-C06:08SRFDEQWNAV0.99480.9961818
NF1-RBX1chr1729422387chr2241349558443HLA-B44:22DEQWNAVALW0.99460.53851121
NF1-RBX1chr1729422387chr2241349558443HLA-B57:02AVVSRFDEQW0.97620.9844515
NF1-RBX1chr1729422387chr2241349558443HLA-B44:21DEQWNAVALW0.9390.50731121
NF1-RBX1chr1729422387chr2241349558443HLA-C06:17SRFDEQWNAV0.87240.9963818
NF1-RBX1chr1729422387chr2241349558443HLA-C06:02SRFDEQWNAV0.87240.9963818
NF1-RBX1chr1729422387chr2241349558443HLA-B15:13DEQWNAVALW0.69520.93361121
NF1-RBX1chr1729422387chr2241349558443HLA-C04:01RFDEQWNAVAL10.9651920
NF1-RBX1chr1729422387chr2241349558443HLA-B57:10QAVVSRFDEQW0.99990.9929415
NF1-RBX1chr1729422387chr2241349558443HLA-C18:01RFDEQWNAVAL0.99990.9593920
NF1-RBX1chr1729422387chr2241349558443HLA-B57:04QAVVSRFDEQW0.99960.8146415
NF1-RBX1chr1729422387chr2241349558443HLA-B57:02QAVVSRFDEQW0.99630.9626415
NF1-RBX1chr1729422387chr2241349558443HLA-B40:36RFDEQWNAVAL0.9420.6845920
NF1-RBX1chr1729422387chr2241349558443HLA-B40:49RFDEQWNAVAL0.85540.6795920

Top

Potential FusionNeoAntigen Information of NF1-RBX1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of NF1-RBX1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
10376VVSRFDEQWNAVALNF1RBX1chr1729422387chr2241349558443

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of NF1-RBX1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN10376VVSRFDEQWNAVAL-7.9962-8.1096
HLA-B14:023BVN10376VVSRFDEQWNAVAL-5.70842-6.74372
HLA-B52:013W3910376VVSRFDEQWNAVAL-6.83737-6.95077
HLA-B52:013W3910376VVSRFDEQWNAVAL-4.4836-5.5189
HLA-A11:014UQ210376VVSRFDEQWNAVAL-10.0067-10.1201
HLA-A11:014UQ210376VVSRFDEQWNAVAL-9.03915-10.0745
HLA-A24:025HGA10376VVSRFDEQWNAVAL-6.56204-6.67544
HLA-A24:025HGA10376VVSRFDEQWNAVAL-5.42271-6.45801
HLA-B44:053DX810376VVSRFDEQWNAVAL-7.85648-8.89178
HLA-B44:053DX810376VVSRFDEQWNAVAL-5.3978-5.5112
HLA-B35:011A1N10376VVSRFDEQWNAVAL-6.27422-6.38762
HLA-B35:011A1N10376VVSRFDEQWNAVAL-5.27424-6.30954
HLA-A02:016TDR10376VVSRFDEQWNAVAL-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of NF1-RBX1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
NF1-RBX1chr1729422387chr22413495581120DEQWNAVALGAGCAGTGGAATGCAGTAGCCCTCTGG
NF1-RBX1chr1729422387chr22413495581121DEQWNAVALWGAGCAGTGGAATGCAGTAGCCCTCTGGGCC
NF1-RBX1chr1729422387chr22413495581220EQWNAVALCAGTGGAATGCAGTAGCCCTCTGG
NF1-RBX1chr1729422387chr22413495581221EQWNAVALWCAGTGGAATGCAGTAGCCCTCTGGGCC
NF1-RBX1chr1729422387chr2241349558415QAVVSRFDEQWGCCGTGGTCAGCCGCTTCGACGAGCAGTGGAAT
NF1-RBX1chr1729422387chr2241349558515AVVSRFDEQWGTGGTCAGCCGCTTCGACGAGCAGTGGAAT
NF1-RBX1chr1729422387chr2241349558615VVSRFDEQWGTCAGCCGCTTCGACGAGCAGTGGAAT
NF1-RBX1chr1729422387chr2241349558617VVSRFDEQWNAGTCAGCCGCTTCGACGAGCAGTGGAATGCAGTA
NF1-RBX1chr1729422387chr2241349558715VSRFDEQWAGCCGCTTCGACGAGCAGTGGAAT
NF1-RBX1chr1729422387chr2241349558717VSRFDEQWNAAGCCGCTTCGACGAGCAGTGGAATGCAGTA
NF1-RBX1chr1729422387chr2241349558817SRFDEQWNACGCTTCGACGAGCAGTGGAATGCAGTA
NF1-RBX1chr1729422387chr2241349558818SRFDEQWNAVCGCTTCGACGAGCAGTGGAATGCAGTAGCC
NF1-RBX1chr1729422387chr2241349558819SRFDEQWNAVACGCTTCGACGAGCAGTGGAATGCAGTAGCCCTC
NF1-RBX1chr1729422387chr2241349558918RFDEQWNAVTTCGACGAGCAGTGGAATGCAGTAGCC
NF1-RBX1chr1729422387chr2241349558920RFDEQWNAVALTTCGACGAGCAGTGGAATGCAGTAGCCCTCTGG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of NF1-RBX1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
OVNF1-RBX1chr1729422387ENST00000356175chr2241349558ENST00000216225TCGA-61-1738

Top

Potential target of CAR-T therapy development for NF1-RBX1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to NF1-RBX1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to NF1-RBX1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneNF1C0027831Neurofibromatosis 144CTD_human;GENOMICS_ENGLAND;UNIPROT
HgeneNF1C1708353Hereditary Paraganglioma-Pheochromocytoma Syndrome10CLINGEN
HgeneNF1C0349639Juvenile Myelomonocytic Leukemia7CTD_human;GENOMICS_ENGLAND;ORPHANET
HgeneNF1C2931482Neurofibromatosis-Noonan syndrome6CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneNF1C0553586Cafe-au-lait macules with pulmonary stenosis5CTD_human;GENOMICS_ENGLAND;ORPHANET
HgeneNF1C0162678Neurofibromatoses3CGI;CTD_human;GENOMICS_ENGLAND
HgeneNF1C0004114Astrocytoma2CTD_human
HgeneNF1C0023467Leukemia, Myelocytic, Acute2CTD_human
HgeneNF1C0025202melanoma2CGI;CTD_human
HgeneNF1C0026998Acute Myeloid Leukemia, M12CTD_human
HgeneNF1C0205768Subependymal Giant Cell Astrocytoma2CTD_human
HgeneNF1C0206727Nerve Sheath Tumors2CTD_human
HgeneNF1C0280783Juvenile Pilocytic Astrocytoma2CTD_human
HgeneNF1C0280785Diffuse Astrocytoma2CTD_human
HgeneNF1C0334579Anaplastic astrocytoma2CTD_human
HgeneNF1C0334580Protoplasmic astrocytoma2CTD_human
HgeneNF1C0334581Gemistocytic astrocytoma2CTD_human
HgeneNF1C0334582Fibrillary Astrocytoma2CTD_human
HgeneNF1C0334583Pilocytic Astrocytoma2CTD_human
HgeneNF1C0338070Childhood Cerebral Astrocytoma2CTD_human
HgeneNF1C0547065Mixed oligoastrocytoma2CTD_human
HgeneNF1C0750935Cerebral Astrocytoma2CTD_human
HgeneNF1C0750936Intracranial Astrocytoma2CTD_human
HgeneNF1C0751689Peripheral Nerve Sheath Neoplasm2CTD_human
HgeneNF1C0751691Perineurioma2CTD_human
HgeneNF1C1704230Grade I Astrocytoma2CTD_human
HgeneNF1C1834235NEUROFIBROMATOSIS, FAMILIAL SPINAL2CTD_human;GENOMICS_ENGLAND;UNIPROT
HgeneNF1C1879321Acute Myeloid Leukemia (AML-M2)2CTD_human
HgeneNF1C0001430Adenoma1CTD_human
HgeneNF1C0004352Autistic Disorder1CTD_human
HgeneNF1C0016057Fibrosarcoma1CTD_human
HgeneNF1C0017636Glioblastoma1CTD_human
HgeneNF1C0017638Glioma1CGI;CTD_human
HgeneNF1C0020796Profound Mental Retardation1CTD_human
HgeneNF1C0023186Learning Disorders1CTD_human
HgeneNF1C0023827liposarcoma1CTD_human
HgeneNF1C0025363Mental Retardation, Psychosocial1CTD_human
HgeneNF1C0026654Moyamoya Disease1GENOMICS_ENGLAND
HgeneNF1C0027809Neurilemmoma1CTD_human
HgeneNF1C0027830neurofibroma1CTD_human
HgeneNF1C0027962Melanocytic nevus1CTD_human
HgeneNF1C0028326Noonan Syndrome1GENOMICS_ENGLAND
HgeneNF1C0031511Pheochromocytoma1CTD_human
HgeneNF1C0035320Retinal Neovascularization1CTD_human
HgeneNF1C0205646Adenoma, Basal Cell1CTD_human
HgeneNF1C0205647Follicular adenoma1CTD_human
HgeneNF1C0205648Adenoma, Microcystic1CTD_human
HgeneNF1C0205649Adenoma, Monomorphic1CTD_human
HgeneNF1C0205650Papillary adenoma1CTD_human
HgeneNF1C0205651Adenoma, Trabecular1CTD_human
HgeneNF1C0205824Liposarcoma, Dedifferentiated1CTD_human
HgeneNF1C0205825Liposarcoma, Pleomorphic1CTD_human
HgeneNF1C0205944Sarcoma, Epithelioid1CTD_human
HgeneNF1C0205945Sarcoma, Spindle Cell1CTD_human
HgeneNF1C0259783mixed gliomas1CTD_human
HgeneNF1C0334588Giant Cell Glioblastoma1CTD_human
HgeneNF1C0555198Malignant Glioma1CTD_human
HgeneNF1C0751262Adult Learning Disorders1CTD_human
HgeneNF1C0751263Learning Disturbance1CTD_human
HgeneNF1C0751265Learning Disabilities1CTD_human
HgeneNF1C0751374Schwannomatosis, Plexiform1CTD_human
HgeneNF1C0917816Mental deficiency1CTD_human
HgeneNF1C0917817Neurofibromatosis 31CTD_human
HgeneNF1C1257877Pheochromocytoma, Extra-Adrenal1CTD_human
HgeneNF1C1261473Sarcoma1CTD_human
HgeneNF1C1330966Developmental Academic Disorder1CTD_human
HgeneNF1C1370889Liposarcoma, well differentiated1CTD_human
HgeneNF1C1621958Glioblastoma Multiforme1CTD_human
HgeneNF1C3150928NF1 Microdeletion Syndrome1ORPHANET
HgeneNF1C3714756Intellectual Disability1CTD_human